查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1692308

骨癌治疗市场 - 全球产业规模、份额、趋势、机会和预测（按骨癌类型、按治疗类型、按地区和竞争细分，2020-2030 年预测）

Bone Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Bone Cancer Type, By Treatment Type, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球骨癌治疗市场价值为 13 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 5.12%。全球骨癌治疗市场是肿瘤学更广泛领域内一个充满活力且不断发展的产业。它致力于解决骨癌带来的独特挑战，骨癌可能是原发性的（起源于骨骼）或继发性的（由身体其他部位的转移引起）。该市场涵盖了旨在诊断、管理和潜在治癒骨癌的各种治疗和疗法。例如，美国癌症协会估计，2022 年将有 3,910 例新的骨癌病例和 2,100 例死亡病例。原发性骨癌很少见，占所有癌症的不到 1%。骨肉瘤是最常见的类型，其次是软骨肉瘤和尤文氏肉瘤。

市场概况
预测期 2026-2030
2024 年市场规模 13亿美元
2030 年市场规模 17.4 亿美元
2025-2030 年复合年增长率 5.12％
成长最快的领域 标靶治疗
最大的市场 北美洲

主要市场驱动因素

技术进步

主要市场挑战

有限的研究经费和资源

主要市场趋势

标靶治疗的进展

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球骨癌治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依骨癌类型（原发性骨癌、继发性骨癌）
    • 依治疗类型（化疗、标靶治疗、放射治疗、手术、其他）
    • 按公司分类（2024）
    • 按地区
  • 市场地图

第六章：北美骨癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 墨西哥
    • 加拿大

第七章：欧洲骨癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太骨癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美骨癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲骨癌治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 埃及

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如果有）
  • 最新动态

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

  • Amgen Inc
  • Baxter Inc
  • Bayer AG
  • ZetaMet technology
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Recordati Group
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 17386

Global Bone Cancer Treatment Market was valued at USD 1.30 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.12% through 2030. The global bone cancer treatment market is a dynamic and evolving sector within the broader field of oncology. It is dedicated to addressing the unique challenges posed by bone cancers, which can be primary (originating in the bone) or secondary (resulting from metastasis from other parts of the body). This market encompasses a wide range of treatments and therapies aimed at diagnosing, managing, and potentially curing bone cancer. For instance, the American Cancer Society estimated 3,910 new bone cancer cases and 2,100 deaths in 2022. Primary bone cancers are rare, comprising less than 1% of all cancers. Osteosarcoma is the most common type, followed by chondrosarcoma and Ewing sarcomas.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.30 Billion
Market Size 2030USD 1.74 Billion
CAGR 2025-20305.12%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Key Market Drivers

Technological Advancements

Technological advancements have played a pivotal role in reshaping the landscape of bone cancer treatment. Modern imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, have revolutionized the diagnosis and staging of bone cancer. These technologies offer unparalleled precision in locating and characterizing tumors, enabling healthcare professionals to make informed decisions about treatment. One of the most significant breakthroughs in bone cancer treatment is the development of targeted therapies. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, targeted therapies focus on specific molecules or pathways within cancer cells. This precision minimizes collateral damage to healthy tissues and reduces the side effects associated with treatment. Technological advancements have also led to the refinement of surgical procedures for bone cancer treatment. Minimally invasive techniques, such as robotic-assisted surgery and laparoscopy, allow for smaller incisions, faster recovery times, and reduced postoperative pain. The emergence of 3D printing technology has transformed the creation of customized prosthetics for bone cancer survivors. These prosthetics are tailored to fit each patient's unique anatomy, providing a higher level of comfort and functionality. This innovation significantly improves the quality of life for individuals who have undergone limb-sparing surgeries.

Key Market Challenges

Limited Research Funding and Resources

One significant challenge faced by the bone cancer treatment market is the relative rarity of bone cancer compared to other types of cancer, such as breast or lung cancer. Because of its lower prevalence, bone cancer research often receives fewer resources and funding allocations. This limitation can impede the development of innovative treatments and therapies specifically tailored to bone cancer. Conducting clinical trials and research related to bone cancer can be financially demanding. The costs associated with patient recruitment, data collection, and the development of new drugs or treatment modalities are substantial. Inadequate funding and resources can hinder the progress of clinical trials and limit the exploration of potential breakthroughs.

Key Market Trends

Advancements in Targeted Therapies

One significant trend in the global bone cancer treatment market is the rapid development of targeted therapies. Rather than employing broad-spectrum treatments like chemotherapy, precision medicine is gaining prominence. This approach involves identifying specific genetic mutations or molecular markers unique to an individual's cancer cells. Targeted therapies are designed to precisely target these markers, disrupting the growth and spread of cancer cells while sparing healthy tissues. This trend is improving treatment outcomes and reducing the side effects associated with traditional therapies. Immunotherapy is another burgeoning trend in bone cancer treatment. This approach harnesses the body's immune system to recognize and attack cancer cells. Immunotherapeutic drugs, such as immune checkpoint inhibitors, are being investigated for their potential to enhance the immune response against bone cancer. The development of personalized immunotherapies tailored to each patient's unique immune profile is on the horizon, offering promising avenues for treatment.

Key Market Players

  • Amgen Inc
  • Baxter Inc
  • Bayer AG
  • ZetaMet Technology
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Recordati Group
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals Inc

Report Scope:

In this report, the Global Bone Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bone Cancer Treatment Market, By Bone Cancer Type:

  • Primary Bone Cancer
  • Secondary Bone Cancer

Bone Cancer Treatment Market, By Treatment Type:

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Surgery
  • Others

Bone Cancer Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bone Cancer Treatment Market.

Available Customizations:

Global Bone Cancer Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Bone Cancer Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Bone Cancer Type (Primary Bone Cancer, Secondary Bone Cancer)
    • 5.2.2. By Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Others)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Bone Cancer Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Bone Cancer Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bone Cancer Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Bone Cancer Type
        • 6.3.1.2.2. By Treatment Type
    • 6.3.2. Mexico Bone Cancer Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Bone Cancer Type
        • 6.3.2.2.2. By Treatment Type
    • 6.3.3. Canada Bone Cancer Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Bone Cancer Type
        • 6.3.3.2.2. By Treatment Type

7. Europe Bone Cancer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Bone Cancer Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Bone Cancer Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Bone Cancer Type
        • 7.3.1.2.2. By Treatment Type
    • 7.3.2. Germany Bone Cancer Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Bone Cancer Type
        • 7.3.2.2.2. By Treatment Type
    • 7.3.3. United Kingdom Bone Cancer Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Bone Cancer Type
        • 7.3.3.2.2. By Treatment Type
    • 7.3.4. Italy Bone Cancer Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Bone Cancer Type
        • 7.3.4.2.2. By Treatment Type
    • 7.3.5. Spain Bone Cancer Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Bone Cancer Type
        • 7.3.5.2.2. By Treatment Type

8. Asia-Pacific Bone Cancer Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Bone Cancer Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bone Cancer Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Bone Cancer Type
        • 8.3.1.2.2. By Treatment Type
    • 8.3.2. India Bone Cancer Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Bone Cancer Type
        • 8.3.2.2.2. By Treatment Type
    • 8.3.3. South Korea Bone Cancer Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Bone Cancer Type
        • 8.3.3.2.2. By Treatment Type
    • 8.3.4. Japan Bone Cancer Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Bone Cancer Type
        • 8.3.4.2.2. By Treatment Type
    • 8.3.5. Australia Bone Cancer Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Bone Cancer Type
        • 8.3.5.2.2. By Treatment Type

9. South America Bone Cancer Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Bone Cancer Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bone Cancer Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Bone Cancer Type
        • 9.3.1.2.2. By Treatment Type
    • 9.3.2. Argentina Bone Cancer Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Bone Cancer Type
        • 9.3.2.2.2. By Treatment Type
    • 9.3.3. Colombia Bone Cancer Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Bone Cancer Type
        • 9.3.3.2.2. By Treatment Type

10. Middle East and Africa Bone Cancer Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Bone Cancer Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bone Cancer Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Bone Cancer Type
        • 10.3.1.2.2. By Treatment Type
    • 10.3.2. Saudi Arabia Bone Cancer Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Bone Cancer Type
        • 10.3.2.2.2. By Treatment Type
    • 10.3.3. UAE Bone Cancer Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Bone Cancer Type
        • 10.3.3.2.2. By Treatment Type
    • 10.3.4. Egypt Bone Cancer Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Bone Cancer Type
        • 10.3.4.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenge

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Amgen Inc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysi
  • 14.2. Baxter Inc
  • 14.3. Bayer AG
  • 14.4. ZetaMet technology
  • 14.5. Johnson & Johnson
  • 14.6. Novartis AG
  • 14.7. Pfizer Inc.
  • 14.8. Recordati Group
  • 14.9. Takeda Pharmaceutical Company
  • 14.10. Eli Lilly and Company
  • 14.11. Spectrum Pharmaceuticals Inc.

15. Strategic Recommendations

16. About Us & Disclaimer